Filgotinib for treating moderate to severe rheumatoid arthritis

2.1 Filgotinib (Jyseleca, Galapagos Biotech Ltd) is 'indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to 1 or more disease-modifying antirheumatic drugs (DMARDs). Filgotinib may be used as monotherapy or in combination with methotrexate'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The list price for filgotinib is £863.10 per bottle of 30-day pack (company submission). The average cost for each patient per year is estimated at £10,508.00 based on the list price. The company has a commercial arrangement. This makes filgotinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.